Notes
The study was funded by Karyopharm Therapeutics.
Reference
Dolph M, et al. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial. PharmacoEconomics : 16 Aug 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01068-9
Rights and permissions
About this article
Cite this article
Multiple myeloma: one-weekly selinexor + bortezomib + dexamethasone cost effective?. PharmacoEcon Outcomes News 885, 16 (2021). https://doi.org/10.1007/s40274-021-07958-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07958-x